Skye Bioscience Secures $68M PIPE, Adds Board Members and CMO
SKYE is trading near its 52-week low of $1.5 (6.0% above the low).
Summary
Skye Bioscience is raising approximately $68 million (up to $72.9 million) through a private investment in public equity (PIPE) from a syndicate including Abingworth, British Business Bank, NEXTBio Capital, and 5AM Ventures. The financing is expected to close in Q4 2026. This capital injection is significant relative to the company's current market capitalization and provides runway for its development programs. Concurrently, the company announced board changes: Andrew Sinclair and Bernard Coulie joined the board, Claire Catherinet resigned, and Mei-Lun Wang was appointed Chief Medical Officer to lead development of RXC008 for FSCD. These moves strengthen the leadership team and signal commitment to advancing the pipeline. The PIPE follows the recent reverse merger with Redx Pharma and a $22 million equity line of credit, indicating continued financial restructuring. Investors will watch for closing of the PIPE and further updates on RXC008 development.
At the time of this announcement, SKYE was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $1.50 to $39.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.